NCR1 and neoplasm: Our results on the anti-NKp46 mAb 09 binder used in our CYT-303 showed that this binder meets both of these criteria as it does not induce internalization of NKp46 or block the binding of NKp46 to its natural ligands expressed on tumor cells.